(DENIM) DC-based immunotherapy to treat Malignant Mesothelioma

Project summary

The consortium aims to commercialize the MMpredictor as a personalized medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients. MM is the second most common form of blood cancer contributing to 15% of all blood cancers and ~1,5% and 2% of all cancer deaths annually in the EU and US, respectively. Patients show a large variability in treatment response and side effects due to tumour heterogeneity and the patient’s intrinsic characteristics. Therefore, not every treatment will be suitable for each patient, and treatment strategies are often based on trial-and-error. The availability of multiple (>20) treatment options complicates treatment decision-making even more. With the current development of many more promising treatments, there is an urgent unmet clinical need for a diagnostic assay that supports personalized cancer treatment in order to improve patient health outcomes, prevent side effects and reduce healthcare costs. In this project, the test’s clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling. The consortium consists of a life science team that combines all the required complementary expertise to successfully bring the MMpredictor to market.

Overall, the consortium aims to commercialize the MM predictor as a personlised medicine tool that predicts the most effective treatment strategy for individual multiple myeloma patients.